Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muAd-Ifna
- Development stage
- Preclinical
- Modality
- Gene Therapies
- Administration
- Intravesical
01
Overview
muAd-Ifna is a murine-specific adenoviral gene therapy vector designed as a research surrogate for nadofaragene firadenovec (Ad-IFNα/Syn3). It consists of a non-replicating adenovirus vector that delivers the gene for murine interferon-alpha (IFNα) to target cells, primarily for the study of bladder cancer in immunocompetent mouse models. Upon intravesical administration, the vector induces the local expression of IFNα, a pleiotropic cytokine that promotes direct tumor cell killing via TRAIL-mediated apoptosis, inhibits angiogenesis, and activates both innate and adaptive immune responses within the tumor microenvironment, including the recruitment and activation of T-cells and macrophages.
- Other names
- muAd-Ifnαmurine adenoviral IFNαAd-mIFNαmurine nadofaragene firadenovec surrogate
Beyond the preview
Go deeper on muAd-Ifna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muAd-Ifna.